Claire Cassedy's blog
Today, KEI submitted comments to the Notice published in the Federal Register on October 5, 2016, entitled “Prospective Grant of Exclusive Patent License: Development of Anti-CD70 Chimeric Antigen Receptors for the Treatment of CD70 Expressing Cancers.” KEI's comments addressed issues with the NIH's processes for granting exclusive licenses, and transparency in those licenses, resulting data, trials, pricing, and revenue.
Democratic presidential nominee Hillary Clinton has published a factsheet presenting, "Hillary's Plan to Respond to Unjustified Price Hikes for Long-Available Drugs."
Today via Twitter, KEI Director James Love offered a six point commentary on Secretary Clinton's proposal to address drug price hikes:
Obama Administration Recommends Senate Ratify Marrakesh Treaty for the Blind; Implementation Language Would Limit ExportsSubmitted by Claire Cassedy on 12. February 2016 - 14:35
CONTACT: Zack Struver
+1 (202) 332-2670
Obama Administration Recommends Senate Ratify Marrakesh Treaty for the Blind; Implementation Language Would Seriously Limit Exports
4 August 2015
FOR IMMEDIATE RELEASE
CONTACT: Zack Struver
+1 (202) 332-2670
Knowledge Ecology International Leaks TPP Text on Intellectual Property
Tuesday, August 4th, 2015
Attached is a 2 page summary of the main provisions in the Trans-Pacific Partnership Agreement (TPP) that will lead to higher prices for drugs and other medical technologies.
A pdf version of the note is available here: http://keionline.org/sites/default/files/KEI-TPP-Briefing-2015-2-A2M.pdf
What does the TPP do as regards prices of drugs and other medical technologies?
KEI TPP Briefing note 2015:2
June 10, 2015
KEI is circulating a sign on letter to be sent to Ambassador Michael Froman of USTR. We learned that in a USTR has been stating that there was no evidence that stronger intellectual property rules created barriers for access to medicine.
This is a shocking statement for USTR to make, and we are seeking confirmation and clarification of USTR's assertion. The text of our letter follows below.
If you would like to sign on to this letter, please send your name, city and state of residence, and affiliation if any, along with contact details (only for confirmation if necessary), to:
On Thursday, May 21, 2015, KEI and KEI Europe hosted a side event at the 68th World Health Assembly on compulsory licensing of patents on drugs, vaccines, and diagnostic tests. The event was graciously hosted by UNAIDS in the Kofi Annan room.
On Friday May 8, 2015, the US Department of Health and Human Services held a listening session to solicit input on the agenda items for the upcoming 68th World Health Assembly. KEI delivered five interventions covering a range of critical WHA topics. The full provisional agenda of the 68th WHA can be accessed here: http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_1-en.pdf
Today, KEI hosted the first talk in a series of seminars on drug pricing. The seminar, conducted via video conference, focused on the Canadian approach to drug pricing. Each seminar in the series is intended to contribute to the discussion on drug pricing and how we can improve affordability and access to medicines. Paul Grootendorst began with a presentation (the slides are available here), before opening up the discussion to questions from those participating in the video conference.
KEI Seminars on Drug Pricing: 30 April 2015, Prof. Paul Grootendorst on the Canadian approach to drug pricingSubmitted by Claire Cassedy on 21. April 2015 - 15:02
On Thursday, 30 April 2015, KEI will host the first talk in a series of seminars on drug pricing. The seminars will take place via video conference (hosted by KEI), and participation is welcome either by attending the presentation at KEI’s Washington, DC offices, or to the extent we are able, joining the digital conference.
On March 18, 2015, KEI, KEI Europe, and Essential Inventions submitted proposals for global voluntary licences for all patents necessary for hepatitis C (HCV) medicines to five drug companies -- AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and Merck.
EB 136 Draft decision passed on the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual PropertySubmitted by Claire Cassedy on 3. February 2015 - 10:58
On Tuesday February 3, 2015, the final day of the 136th WHO Executive Board meeting, the EB passed a draft decision on the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property (GSPoA). The draft decision recommends to the WHA that the GSPOA be extended until 2022.
EB 136 Friday, January 30th: Discussion of Consultative Expert Working Group on Research Development-Financing and CoordinationSubmitted by Claire Cassedy on 31. January 2015 - 3:35
Another matter considered during the Friday, January 30th session of the WHO Executive Board was the "Follow-up of the report on the Consultative Expert Working Group on Research Development-Financing and Coordination." In addition to the general report on the CEWG, the EB also considered the Director General's report on the CEWG "Health research and development demonstration projects."
EB 136 Friday, January 30th: Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual PropertySubmitted by Claire Cassedy on 30. January 2015 - 11:25
On Friday, January 30th, the WHO Executive Board discussed the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property (GSPA). The discussion covered several documents in relation to the GSPoA, including:
EB 136 Tuesday January 28: WHO Engagement with Non-state Actors; US issues apology to the African GroupSubmitted by Claire Cassedy on 28. January 2015 - 5:24
During Tuesday's session of the WHO Executive Board, the board considered a proposal from Argentina on the table for a "Framework of Engagement with Non-state Actors." Many states, both Board members and non-Executive Board member states, contributed to the discussion, citing the issue as a critical reform issue for the WHO. While a number of states took issue with some of the specifics of the draft proposal, for example that at current time all types of non-state actors were lumped together (i.e.